Systemic anti-cancer therapy: management options for people with squamous non-small cell carcinoma

This is a summary of the recommendations on management options for people with squamous cell carcinoma from the NICE guideline on lung cancer. See www.nice.org.uk/guidance/NGXX, and see technology appraisals for full details.

© NICE 2018. All rights reserved. Subject to Notice of rights.


PD-L1 <50%
- Gemcitabine + Carboplatin* or Cisplatin
- Vinorelbine + Carboplatin or Cisplatin

PD-L1 ≥50%
- Pembrolizumab (TA531)
- Gemcitabine + Carboplatin* or Cisplatin
- Vinorelbine + Carboplatin or Cisplatin

Disease progression

Cancer Drugs Fund

The gemcitabine and carboplatin combination does not have a UK marketing authorisation for this indication

Atezolizumab (no PD-L1 expression needed) (TA520)
- or
Nivolumab (no PD-L1 expression needed) (TA483)
- or
Pembrolizumab (if PD-L1 >1%) (TA428)

Docetaxel

Docetaxel

PD-L1 ≥50%
- Pembrolizumab (TA531)
- Gemcitabine + Carboplatin* or Cisplatin
- Vinorelbine + Carboplatin or Cisplatin

Disease progression

Cancer Drugs Fund

The gemcitabine and carboplatin combination does not have a UK marketing authorisation for this indication

Atezolizumab (no PD-L1 expression needed) (TA520)
- or
Nivolumab (no PD-L1 expression needed) (TA483)
- or
Pembrolizumab (if PD-L1 >1%) (TA428)

Docetaxel

Docetaxel